Generation and characterization of monoclonal antibodies against thyroid-stimulating hormone for newborn screening of congenital hypothyroidism

ABSTRACT

Congenital hypothyroidism (CH) is one of the most frequent inherited-metabolic diseases in the world, and the main cause of treatable mental retardation in children. Because signs and symptoms of this disease are often scarce and not easily recognizable, newborns are screened for the early CH detection at birth. The Center of Immunoassay (CIE) has developed the UMELISA® TSH Neonatal and UMELISA® TSH to determine neonatal thyroid-stimulating hormone (TSH) levels in dried blood and serum samples. Both reagent kits use the same polystyrene plates coated with anti-β-TSH monoclonal antibodies (MAbs), but one of these is commercially acquired. Obtaining appropriate anti-TSH MAbs at the CIE would guarantee economic independence and security in the production of these kits. Immunization of mice with TSH led to the generation of 7G11E3, an anti-β-TSH IgG1-secreting hybridoma. The high affinity of 7G11E3 MAb and its characteristic epitopic recognition explain its better performance when adsorbed to UMELISA® plates for capturing low amounts of TSH in comparison with the studied MAbs. Performance of assays using polystyrene plates coated with 7G11E3 MAb was studied. Recovery percentages (100.0–106.7% for UMELISA® TSH NEONATAL and 97.3–99.0% for UMELISA® TSH) and intra (5.2–7.9% for UMELISA® TSH NEONATAL and 3.2–5.3% for UMELISA® TSH) and inter (6.6–7.7% for UMELISA® TSH NEONATAL and 5.2–8.0% for UMELISA® TSH) coefficients of variation were similar to the ones described for the commercial kits. Limits of detection and quantification were 1.0 and 3.8 mIU/L for UMELISA® TSH NEONATAL, and 0.3 and 0.6 mIU/L for UMELISA® TSH, respectively. The results also showed high overall concordance between assays (n = 2 019, ρc = 0.90 for UMELISA® TSH NEONATAL and n = 200, ρc = 0.94 for UMELISA® TSH). The 7G11E3 MAb meets the requirements for its use in the plates of UMELISA® TSH kits for CH newborn screening in Cuba.

Abbreviations: CECMED, Center for the State Control of Medicaments and Medical Equipment and Devices; CH, congenital hypothyroidism; CIE, Center of Immunoassay; CLSI, Clinical and Laboratory Standards Institute; CV coefficient of variation; DBS, dried blood spots; LOB, limit of blank; LOD, limit of detection; LOQ, limit of quantitation; SD, standard deviation; S_r, repeatability standard deviation; SUMA, Ultra Micro Analytic System; UMELISA, ultramicro enzyme-linked immunosorbent assay.

KEYWORDS:

• Monoclonal antibodies
• thyroid-stimulating hormone
• congenital hypothyroidism

Article highlights

- The 7G11E3 monoclonal antibody recognizes two epitopes of the β-TSH.

- The distinctive epitopic recognition of the 7G11E3 high affinity monoclonal antibody explains its ability for capturing low amounts of TSH.

- Use of 7G11E3 monoclonal antibody in plates of the UMELISA® TSH Neonatal and UMELISA® TSH maintains these assays’ quality indicators.

Acknowledgments

The authors are indebted to BEd. José Luis Fernández Sierra for his valuable help in the final language revision of the manuscript.

Disclosure

The authors have nothing to disclose